1	Accuracy of rapid antigen testing for COVID-19 in shelter settings
2	
3	Yasmin Garad, MSc ¹ ; Andreea A. Manea, BSc ¹ ; Negin Pak, BSc ¹ , Bronwyn Barker, MPH ¹ ,
4	Danielle Kasperavicius, MPH ¹ , Lames Danok, BSc ¹ , Stefan Baral, MD, FRCPC, CCFP ^{1,2,3} ,
5	Aaron M. Orkin, MD, MSc, MPH, PhD ⁴ , Amna Siddiqui, BScN ² , Sharon E. Straus, MD, MSc
6	^{1,6,7} , Christine Fahim, PhD, MSc ^{1,8}
7	
8	Affiliations
9	¹ Knowledge Translation Program, St. Michael's Hospital, Unity Health Toronto, Toronto, ON,
10	Canada
11	² Inner City Health Associates, Toronto, ON, Canada
12	³ Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD, United
13	States
14	⁴ St. Joseph's Health Centre, Unity Health Toronto, Toronto, ON, Canada
15	⁵ Department of Family and Community Medicine and Dalla Lana School of Public Health,
16	University of Toronto, Toronto, ON, Canada
17	⁶ Department of Medicine, University of Toronto, Toronto, ON, Canada
18	⁷ Division of Geriatrics, Department of Medicine, St. Michael's Hospital, Unity Health Toronto,
19	Toronto, ON, Canada
20	⁸ Institute of Health Policy, Management and Evaluation, University of Toronto, 155 College St.,
21	Toronto, ON M5T 3M6
22	
23	*Corresponding author:
24	Christine Fahim, PhD
25 26	Scientist, Knowledge Translation Program St. Michael's Hospital Unity Health Toronto
27	Christine.Fahim@unityhealth.to
28	

29 Abstract

30 Background

- 31 The COVID-19 pandemic disproportionally affected congregate living settings, including
- 32 shelters. COVID-19 transmission can have more adverse outcomes in these settings due to the
- 33 vulnerability of residents. Point of care rapid antigen testing (RAT) represents a strategy with
- 34 potential benefits for COVID-19 detection in shelters, including rapid results, ease of use, cost-
- 35 effectiveness, and early detection.

36 Objectives

- 37 Our primary objective was to assess the real-world test accuracy of RAT for COVID-19 using the
- 38 Quidel Sofia 2 Flu + SARS Antigen fluorescent immunoassay (Sofia RAT) compared to
- 39 polymerase chain reaction (PCR) testing among shelter residents in Ontario, Canada.

40 Study Design

- 41 A consecutive sample of 102 residents across six shelters who were symptomatic for, or exposed
- 42 to COVID-19 were included. The RAT and PCR samples were taken on the same day for each
- 43 participant. Results from the Sofia RAT were compared to PCR test results to determine test
- 44 accuracy. Participant demographic data could not be collected due to workforce constraints.
- 45 **Results**
- 46 We reported our methods and findings using the QUality Assessment tool of Diagnostic
- 47 Accuracy Studies (QUADAS-2) guidelines. Sofia 2 RAT specificity was 97.9% (95% CI: 92.7%
- 48 to 99.7%) for COVID-19 compared to PCR. Due to a lack of true positive cases, sensitivity
- 49 could not accurately be calculated (0.00% (95% CI: 0.00% to 52.2%)).

50 Conclusion

51 These data suggest that the Sofia RAT is a highly specific test for COVID-19.

52 Keywords

Rapid antigen testing (RAT), Homeless shelter, Test accuracy, COVID-19 detection, SARSCoV-2

55 Background

56	COVID-19 disproportionally affected individuals in homeless shelter settings ^{1,2} . Individuals in
57	these settings experience a greater risk of physical frailty, comorbidity, and being
58	immunocompromised than the general population ²⁻⁵ . These risk factors in combination with
59	crowded conditions likely contributed to higher rates of COVID-19 in these settings ^{2,6} .
60	Point of care rapid antigen testing (RAT) provides multiple benefits for COVID-19
61	detection compared to laboratory-based testing such as polymerase chain reaction (PCR) ⁷ . It is a
62	streamlined alternative, which compared to laboratory-based testing typically has shorter
63	processing times, does not require specific expertise for sample collection and handling, and is
64	more cost-effective ⁷⁻¹⁰ .
65	During the COVID-19 pandemic, RAT was used as a low-barrier and cost-effective tool

for early detection^{11,12}. As the pandemic evolved, new multiplex RAT point of care testing 66 67 became available including the Sofia 2 Flu + SARS Antigen fluorescent immunoassay (FIA; hereafter Sofia RAT) developed by Quidel Corporation¹³. Due to its ability to simultaneously 68 69 detect respiratory infections that share similar clinical presentations, such as COVID-19 and 70 influenza, multiplex RAT can help to facilitate a streamlined approach to surveillance and diagnosis in shelter settings¹⁴. To our knowledge, there are limited data regarding the 71 72 performance of Sofia RAT compared to PCR testing for COVID-19 in shelter settings. **Objectives** 73

74	Our main objective was to assess the real-world test accuracy of RAT for COVID-19 using the
75	Sofia RAT compared to PCR testing among individuals in homeless shelters.
76	Study Design
77	We reported our methods and findings in accordance with the QUality Assessment tool of
78	Diagnostic Accuracy Studies (QUADAS-2) ¹⁵ . The project was conducted through St. Michael's
79	Hospital (Toronto, Ontario) from October 2022 until March 2023. Ethical approval was obtained
80	from the Unity Health Toronto Research Ethics Board (REB# 21-319).
81	A consecutive sample of residents across six shelters in Toronto, Ontario who were
82	symptomatic or exposed to COVID-19 were included. Shelters offer temporary accommodation
83	and support services to people experiencing homelessness (PEH). Participants were recruited by
84	nursing staff who conducted routine rapid antigen testing across the six shelters. Residents who
85	expressed interest and provided verbal consent were included in the study and compensated with
86	a \$20 (CAD) gift card for their participation.
87	Multiplex RAT was implemented, which used immunofluorescence technology to
88	simultaneously detect nucleocapsid protein from influenza A, influenza B and SARS-CoV-2. The
89	Sofia RAT was used in combination with the benchtop Sofia 2 FIA analyzer ^{13,16,17} . This analyzer
90	generated results in 15 minutes ¹⁷ .
91	Following informed verbal consent from participants, PCR samples were collected
92	through a nasal or nasopharyngeal swab by a registered nurse at the same encounter where the
93	Sofia RAT was conducted. The PCR sample was transported to St. Michael's Hospital for
94	analysis within 48 hours of sample collection. The results were then reported to the study team

95 by the St. Michael's Hospital microbiology lab by fax and were also publicly reported to Toronto

- 96 Public Health, in accordance with provincial reporting requirements¹⁸. Positive results were
- 97 reported to the participant within 72 hours post-collection.
- 98 Statistical analyses were conducted using Stata version 18¹⁹. All measures of diagnostic
- 99 accuracy were estimated using Stata's diagti command.
- 100 Results
- 101 In total, 102 individuals participated in the study. Sofia 2 RAT specificity was found to be 97.9%
- 102 (95% CI: 92.7% to 99.7%) (see Table 1). The percent of negative test results that were correctly
- identified (NPV) was 95.0% (88.7% to 98.4%) (see Table 1). Due to a lack of positive cases,
- sensitivity and positive predictive value could not be accurately calculated.

Population	Positive Results PCR	Negative Results PCR
(n = 102)	n(%)	n(%)
Positive Results Sofia RAT (n (%))	0(0%)	2(2%)
Negative Results Sofia RAT (n (%))	5(5%)	95(93%)
Sensitivity	0.0% (0.0% to 52.2%)	
Specificity	97.9% (92.7% to 99.7%)	
Positive Likelihood Ratio	0.00	
Negative Likelihood Ratio	1.02 (0.99 to 1.05)	
Positive Predictive Value*	0.00 (0.0% to 84.2%)	
Negative Predictive Value*	95.0% (88.7% to 98.4%)	

Table 1. Comparison of Sofia RAT performance with PCR

106 Discussion

- 107 We determined that among individuals who were exposed or symptomatic for COVID-19, real
- 108 world specificity for case detection using the Sofia RAT compared to PCR was high²⁰. These
- 109 results on specificity for the Sofia RAT meet the criteria set by the World Health Organization
- 110 (WHO) to be considered an acceptable substitute to PCR testing (i.e. sensitivity \geq 80% and
- specificity $\ge 97\%$)²¹ in real world settings. However, we were unable to determine reliable results
- 112 for sensitivity due to a lack of positive test results in our sample. Due to this, the conclusions that

can be drawn regarding the application of the Sofia RAT based on the findings of this study arelimited.

115	Our findings on specificity for the Sofia RAT are also aligned with those of a recent	
116	Cochrane review which demonstrated that the Sofia RAT was one of only two RAT tests that met	
117	the WHO standards for specificity regardless of whether participants were symptomatic (i.e.,	
118	99.4% (98.7% to 99.8%)) or asymptomatic (i.e., 99.7% (99.3% to 99.8%)) ²²⁻²⁸ . Several other	
119	studies similar to ours have demonstrated high specificity over 95% for COVID-19 for RAT	
120	using the Sofia 2 analyzer ²²⁻²⁹ . However, to our knowledge no previous studies have assessed the	
121	accuracy of the Sofia RAT in shelter settings.	
122	In the Cochrane review noted above, the Sofia RAT was also one of seven rapid antigen	
123	tests that met acceptable performance standards for sensitivity for symptomatic participants (i.e.,	
124	80.0% (71.5% to 86.4%)) but did not meet these standards for asymptomatic individuals (i.e.,	
125	41.2% (18.4% to 67.1%). Rates of sensitivity for COVID-19 using the Sofia-2 RAT vary widely	
126	in the literature ²²⁻²⁸ . Given the lack of routine and rapid access to PCR testing in shelter settings	
127	and the option to use the Sofia-2 Analyzer to test for multiple infectious diseases, this test may be	
128	a useful option to support the early detection of infectious disease in these settings ^{30,31} .	
129	Given its high specificity, this diagnostic tool is unlikely to have many false positives	
130	meaning that there is a low risk of diagnostic delay ³² . Furthermore, this decreased diagnostic	
131	delay can improve outbreak response, including individual clinical response like linkage to	
132	treatment, but also public health response including supportive isolation. Overall, despite the risk	
133	of false negatives, the use of rapid testing as a first step may be effective in reducing costs,	
134	laboratory staff burden, and the risk of transmission by detecting some cases quickly and	
135	implementing infection prevention and control practices ^{7,9,22} .	

6

136	This study has some limitations. First, due to a lack of positive cases we were unable to	
137	determine a reliable estimate of sensitivity. Second, due to a lack of feasibility we were not able	
138	to distinguish between symptomatic and asymptomatic participants or measure the viral load for	
139	each sample, which may have impacted test accuracy ³³ . Lastly, for similar reasons, we were not	
140	able to collect demographic data. However, our findings reflect the real-world circumstances	
141	under which diagnostic testing occurs. Despite these limitations, our findings still show high	
142	levels of accuracy in shelter settings for detecting the absence of COVID-19 using the Sofia	
143	RAT.	
144	Conclusion	
144 145	Conclusion Findings from our study demonstrated high specificity for COVID-19 testing using the Sofia	
144 145 146	Conclusion Findings from our study demonstrated high specificity for COVID-19 testing using the Sofia RAT, however we were unable to reliably report sensitivity due to the lack of true positive cases.	
144 145 146 147	Conclusion Findings from our study demonstrated high specificity for COVID-19 testing using the Sofia RAT, however we were unable to reliably report sensitivity due to the lack of true positive cases. Individuals in shelter settings may be at greater risk of infection due to age, comorbid conditions,	
144 145 146 147 148	Conclusion Findings from our study demonstrated high specificity for COVID-19 testing using the Sofia RAT, however we were unable to reliably report sensitivity due to the lack of true positive cases. Individuals in shelter settings may be at greater risk of infection due to age, comorbid conditions, and/or precarious housing ³ . Multiplex testing using rapid tests such as the Sofia RAT in homeless	
144 145 146 147 148 149	Conclusion Findings from our study demonstrated high specificity for COVID-19 testing using the Sofia RAT, however we were unable to reliably report sensitivity due to the lack of true positive cases. Individuals in shelter settings may be at greater risk of infection due to age, comorbid conditions, and/or precarious housing ³ . Multiplex testing using rapid tests such as the Sofia RAT in homeless shelter settings can support the rapid differential diagnosis of infectious diseases with similar	
144 145 146 147 148 149 150	Conclusion Findings from our study demonstrated high specificity for COVID-19 testing using the Sofia RAT, however we were unable to reliably report sensitivity due to the lack of true positive cases. Individuals in shelter settings may be at greater risk of infection due to age, comorbid conditions, and/or precarious housing ³ . Multiplex testing using rapid tests such as the Sofia RAT in homeless shelter settings can support the rapid differential diagnosis of infectious diseases with similar symptoms, allowing for appropriate infection prevention and control measures to be taken more	

152 Declaration of Competing Interests

153 The authors declare that they have no competing interests.

154 Availability of data and materials

155 The datasets generated for this study are not publicly available to protect the privacy of

156 participants and related REB confidentiality requirements. De-identified can be made upon

157 request.

158 Funding

159 This study was funded by Health Canada (Grant # 2122-HQ-000078).

160 Acknowledgements

- 161 The authors would like to express their gratitude to all subjects for their engagement in this
- 162 study. We would also to thank Elizabeth Birkurovitz, Tina Kaur, Princilla Agyemang, Grace
- 163 Richandi for their contributions to the data collection for this study and manuscript review. SES
- 164 was funded by a Tier 1 Canada Research Chair.

165	References
166	
167	1. Richard L, Nisenbaum R, Brown M, et al. Incidence of SARS-CoV-2 Infection Among
168	People Experiencing Homelessness in Toronto, Canada. JAMA Netw Open 2023; 6(3): e232774.
169	2. Baral S, Bond, A., Boozary, A., Bruketa, E., Elmi, N, Freiheit, S. D., Ghosh, M., Goyer, M. E.,
170	Orkin, A. M., Patel, J., Richter, T., Robertson, A., Sutherland, C., Svoboda, T., Turnbull, J., Wong,
171	A., and Zhu, A Seeking shelter: homelessness and COVID-19. FACETS 2021; 6: 925-58.
172	3. Fazel S, Geddes JR, Kushel M. The health of homeless people in high-income countries:
173	descriptive epidemiology, health consequences, and clinical and policy recommendations.
174	Lancet 2014; 384 (9953): 1529-40.
175	4. Tsai J, Wilson M. COVID-19: a potential public health problem for homeless populations.
176	<i>Lancet Public Health</i> 2020; 5 (4): e186-e7.
177	5. Leung CS, Ho MM, Kiss A, Gundlapalli AV, Hwang SW. Homelessness and the response to
178	emerging infectious disease outbreaks: lessons from SARS. J Urban Health 2008; 85(3): 402-10.
179	6. Baggett TP, Gaeta JM. COVID-19 and homelessness: when crises intersect. <i>Lancet Public</i>
180	<i>Health</i> 2021; 6 (4): e193-e4.
181	7. Kalia R, Kaila R, Kahar P, Khanna D. Laboratory and Point-of-Care Testing for COVID-19: A
182	Review of Recent Developments. <i>Cureus</i> 2022; 14 (8): e28530.
183	8. Stall NM, Jones A, Brown KA, Rochon PA, Costa AP. For-profit long-term care homes and
184	the risk of COVID-19 outbreaks and resident deaths. CMAJ 2020; 192 (33): E946-E55.
185	9. Woodbridge Y, Goldberg Y, Amit S, Kopelman NM, Mandel M, Huppert A. Public health-
186	focused use of COVID-19 rapid antigen and PCR tests. <i>Sci Rep</i> 2024; 14 (1): 1430.
187	10. Dinnes J, Deeks JJ, Berhane S, et al. Rapid, point-of-care antigen and molecular-based
188	tests for diagnosis of SARS-CoV-2 infection. <i>Cochrane Database Syst Rev</i> 2021; 3 (3): CD013705.
189	11. Cheng CC, Liu CC, Chiu TF, Shiou-Sheng Chen S. Evaluation of a Rapid Antigen Test for the
190	Diagnosis of SARS-CoV-2 during the COVID-19 Pandemic. <i>Inquiry</i> 2022; 59 : 469580221105354.
191	12. Zirbes J, Sterr CM, Keller C, Engenhart-Cabillic R, Nonnenmacher-Winter C, Gunther F.
192	Emclency analysis of rapid antigen test based SARS-CoV-2 in nospital contact tracing and
193	screening regime: test characteristics and cost effectiveness. <i>Diagn Microbiol Inject Dis</i> 2023;
194	106(4): 115991. 12 Ouidel Safie SARS Antigen ElA Reckage Insert 2020
195	13. Quidel. Solid SARS Antigen FIA Package Insert, 2020.
190	14. BOUKI N, Fidmand C, Ched KL, et al. One Assay to fest mem All: Comparing Multiplex
197	Assays for Expansion of Respiratory virus Surveinance. <i>MedRXiv</i> 2023.
198	15. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality
199	assessment of diagnostic accuracy studies. Ann intern wed 2011, 155 (6), 529-50.
200	ovaluation of the Sofia SAPS CoV-2 antigon assay in a large tortiary care bosnital <i>J Clin Virol</i>
201	2021 · 1/10 · 10/85/
202	2021, 140 . 104034. 17 OuidelOrthe Corneration Sofia® 2 Elucrescent Immunoassay Analyzer 2023
203	17. Quidelof the corporation. Sona 2 Habrescent minuteassay Analyzer. 2023.
204	19 StataCorn Stata Statistical Software: Release 18 College Station TX: StataCorn LLC:
205	2023
207	20. Simundic AM. Measures of Diagnostic Accuracy: Basic Definitions $EIIECC$ 2009: 19 (A):
208	203-11.
200	

209 World Health Organization. COVID-19 Target product profiles for priority diagnostics to 21. 210 support response to the COVID-19 pandemic v.1.0. 2020. 211 https://www.who.int/publications/m/item/covid-19-target-product-profiles-for-priority-212 diagnostics-to-support-response-to-the-covid-19-pandemic-v.0.1. 213 Dinnes J, Sharma P, Berhane S, et al. Rapid, point-of-care antigen tests for diagnosis of 22. 214 SARS-CoV-2 infection. Cochrane Database Syst Rev 2022; 7(7): CD013705. Brihn A, Chang J, K OY, et al. Diagnostic Performance of an Antigen Test with RT-PCR for 215 23. 216 the Detection of SARS-CoV-2 in a Hospital Setting - Los Angeles County, California, June-August 217 2020. MMWR Morb Mortal Wkly Rep 2021; 70(19): 702-6. 218 Smith RD, Johnson JK, Clay C, et al. Clinical evaluation of Sofia Rapid Antigen Assay for 24. 219 detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among emergency 220 department to hospital admissions. Infect Control Hosp Epidemiol 2022; 43(8): 968-73. 221 25. Cernila M, Logar M, Mozina H, Osredkar J. Comparison between the Sofia SARS Antigen 222 FIA Test and the PCR Test in Detection of SARS-CoV-2 Infection. Lab Med 2022. 223 26. Pray IW, Ford L, Cole D, et al. Performance of an Antigen-Based Test for Asymptomatic 224 and Symptomatic SARS-CoV-2 Testing at Two University Campuses - Wisconsin, September-225 October 2020. MMWR Morb Mortal Wkly Rep 2021; 69(5152): 1642-7. 226 27. Gomez Marti JL GJ, McCullough M, Mallon A, Acero J, Kinzler A, et al. Differences in 227 detected viral loads guide use of SARS-CoV-2 antigen-detection assays towards symptomatic 228 college students and children. medRxiv 2021. 229 28. Porte L, Legarraga P, Vollrath V, et al. Evaluation of a novel antigen-based rapid detection 230 test for the diagnosis of SARS-CoV-2 in respiratory samples. Int J Infect Dis 2020; 99: 328-33. 231 29. Jaaskelainen AE, Ahava MJ, Jokela P, et al. Evaluation of three rapid lateral flow antigen 232 detection tests for the diagnosis of SARS-CoV-2 infection. J Clin Virol 2021; 137: 104785. 233 30. Tong R. COVID-19 in Skilled Nursing Homes and Other Long-Term Care Facilities (LTCFs): 234 Could Stronger Public-Health Measures Have Made a Difference? Ethical Public Health Policy 235 Within Pandemics: Springer Cham; 2022. 236 Paat YF, Morales, J., Escajeda, A. I., & Tullius, R. Insights from the shelter: Homeless 31. 237 shelter workers' perceptions of homelessness and working with the homeless. Journal of 238 Progressive Human Services 2021; 32: 263-83. 239 Trevethan R. Sensitivity, Specificity, and Predictive Values: Foundations, Pliabilities, and 32. 240 Pitfalls in Research and Practice. Front Public Health 2017; 5: 307. 241 33. Pradas LV, N.; Hannen, J.; Schölz, C.; Schubert, A.; Knote, R.; Wille, L.; Kleinow, P.; Heuer, 242 A.; Weckesser, V.; et al. Comparison of SARS-CoV-2 Antigen Tests in Asymptomatic Testing of 243 Passengers at German Airports under Time Constraints: Application of Three Different Antigen 244 Test Formats. COVID 2021; 1(3): 546-54. 245